Particles for cell adhesion and use thereof

Cell adhesion particles with intermediate water content facilitate the selective adhesion and separation of tumor and stem cells from blood, addressing non-specific binding and detachment issues, enabling efficient recovery and culture of target cells.

JP7586496B2Active Publication Date: 2024-11-19KYUSHU UNIV

Patent Information

Application Number
JP2021512112
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-18
Filing Date
2020-03-30
Publication Date
2024-11-19
Estimated Expiration
2040-03-30

AI Technical Summary

Technical Problem

Existing methods for selectively adhering and separating target cells, such as tumor cells and stem cells, from blood using antibodies face challenges like non-specific binding, loss of target cells due to antibody changes, and potential damage during detachment, limiting their use in biological evaluations.

Method used

The use of cell adhesion particles with a hydratable composition containing intermediate water (1-30 wt%) that selectively adhere to highly adhesive cells, allowing them to form a complex which can be easily separated and detached without antibodies, using particles with a diameter of 2-500 μm, enabling selective adhesion and separation of cells like tumor cells and stem cells from blood.

Benefits of technology

The method allows for efficient and non-damaging separation of target cells from blood, preserving their viability for further culture and evaluation, by utilizing the selective adhesion properties of intermediate water-containing particles, which autonomously detach in culture medium.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586496000009
    Figure 0007586496000009
  • Figure 0007586496000010
    Figure 0007586496000010
  • Figure 0007586496000011
    Figure 0007586496000011
Patent Text Reader

Abstract

Particles for cell adhesion to be used for adhering highly adhesive cells present in an aqueous solution, said particles for cell adhesion comprising, in at least a part of the surface thereof, a wettable composition having an intermediate water content in the water-saturated state of 1-30 wt%.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to cell adhesion particles for selectively adhering and separating specific cells present in blood or the like in a living body, and a method for selectively adhering and capturing specific cells present in blood or the like using the cell adhesion particles. This application claims priority based on Japanese Patent Application No. 2019-69462 filed in Japan on March 30, 2019, and Japanese Patent Application No. 2019-79696 filed in Japan on April 18, 2019, the contents of which are incorporated herein by reference. [Background technology]

[0002] Traditionally, biopsies have been performed clinically to collect tissue from the lesion site and perform various tests. However, general biopsies involve tissue resection, which is problematic in that they are highly invasive to the patient. In response to this, a technique called "liquid biopsy" has become widespread in recent years. In liquid biopsies, bodily fluids such as blood and saliva are collected from the patient and the target substances contained in the bodily fluids are analyzed mainly by instrumental analysis. Liquid biopsies have the advantage of being less invasive to the patient and being able to obtain a variety of information at low cost. In conventional liquid biopsies, the main test subjects were molecules such as lipids and proteins that exist in the bodily fluids in solution, but there is a demand for collecting tumor cells present in the bodily fluids, especially for the purpose of cancer treatment. In the field of regenerative medicine, stem cells present in the body are collected and cultured for use in treatment, so it is desirable to collect stem cells in a less invasive manner similar to biopsy.

[0003] Typically, blood and lymph are used as body fluids from which tumor cells and stem cells can be collected. On the other hand, the majority of cells contained in blood and lymph are blood cells such as red blood cells, white blood cells, and platelets, and tumor cells and stem cells are present at very low frequencies. For this reason, when collecting target cells from body fluids such as blood, a process is essential to selectively collect target cells present at low frequencies from blood cells and other cells present at high density and frequency in the body fluid, and various methods to achieve this are being investigated.

[0004] Known methods for separating target cells include, for example, a method for separating and collecting cells using a filter or centrifugation by utilizing differences in cell size, a method for separating and collecting cells using a microfluidic device by utilizing differences in dielectrophoretic properties, etc. Also known is a method for adhering and recovering target cells to a surface on which a ligand such as an antibody against a membrane antigen of the target cells is immobilized, utilizing the selective binding property of the antibody.

[0005] Furthermore, as a method for separating specific cell types that exist at low density in blood, etc., a method has been considered in which fine particles with ligands such as antibodies immobilized thereon are attached to target cells for separation. In the method using fine particles as ligand carriers, the specific surface area of ​​the surface for adhering cells can be increased, and therefore it is particularly suitable for adhering rare cell types that exist in blood, etc.

[0006] As an example of the use of carrier particles having immobilized ligands, Patent Document 1 describes a technology for counting circulating tumor cells (CTCs) by selectively adhering and separating CTCs using colloidal magnetic particles (antibody-magnetic particle complexes) having a particle size of 90 to 150 nm to which anti-EpCAM antibodies against EpCAM (epithelial cell adhesion molecule), which is expressed in many carcinomas, are immobilized; this technology is put to practical use as the Cell Search system.

[0007] Patent Document 1 describes the following characteristics required for particles that selectively adhere target cells such as CTCs: i) an antibody as a biological ligand that specifically reacts with target cells is bound to the particle surface, ii) the particles have a size of 90 to 150 nm and can be suspended in a colloidal state in an aqueous solution in order to ensure an opportunity for binding with target cells present in a specimen, iii) the particles are magnetic particles in order to separate target cells that have adhered to the particles by application of a magnetic field, and iv) the particles are coated with a sufficient amount of a base coating material in order to prevent biopolymers and the like present in a living body from nonspecifically binding to the particles (paragraphs 0012 to 0015). In addition, as an example, it is described that magnetic particles of 90 to 150 nm that are base-coated with bovine serum albumin (BSA) or the like and have anti-EpCAM antibodies immobilized thereon functioned favorably (paragraphs 0032 to 0038).

[0008] Furthermore, Patent Document 1, which is intended for counting CTCs and the like, describes that the above-mentioned nanometer-sized magnetic particles are sufficiently small compared to cells that they do not interfere with counting and therefore do not need to be removed from cells before analysis (paragraph 0033), and that in an example in which 28 μm particles are used, it is necessary to detach the magnetic particles bound to cells by, for example, a method of detaching the magnetic particles by replacing the antibody bound to the cell surface with a specified reagent, or a method of severing the bond between the antibody and the magnetic particle with a specified reagent and detaching only the magnetic particles (paragraph 0041). For the above reasons, the cells obtained by the means described in Patent Document 1 are cells with nanometer-sized magnetic particles attached or cells whose surface structure has been modified to detach the magnetic particles, and therefore the use of the recovered cells is limited to simple counting, etc., and it is thought that the process of culturing, etc. after recovery makes them unsuitable for various biological evaluations.

[0009] Patent document 2 and other documents also describe a technology for selectively adhering specific stem cells using carrier particles such as magnetic beads to which a specific antibody is immobilized. However, since the stem cells are attached to the carrier particles by binding an antibody to their surface, it is expected that the same problems as those in Patent Document 1 above will arise.

[0010] On the other hand, the present inventors have found that when a hydratable composition such as a group of polymers is hydrated, some of the hydrated water molecules become defined as intermediate water, and that the surface on which this intermediate water exists is excellent in blood compatibility, such as the difficulty of blood components (platelets, white blood cells, complement, coagulation system, etc.) adhering (Non-Patent Document 1). In addition, they have found that even on a surface that is difficult for blood components to adhere to due to the inclusion of intermediate water, tumor cells such as metastatic cancer cells, stem cells, vascular endothelial cells, etc. contained in blood, etc., can adhere (Patent Document 3). Furthermore, they have revealed that a surface containing a certain proportion of intermediate water is suitable for culturing various types of cells (Patent Document 4). [Prior art documents] [Patent documents]

[0011] [Patent Document 1] Special Publication No. 2002-503814 [Patent Document 2] JP 2010-104350 A [Patent Document 3] JP 2012-105579 A [Patent Document 4] JP 2016-63801 A [Non-patent literature]

[0012] [Non-Patent Document 1] Biomaterials 28-1, 2010, p.34-46 Summary of the Invention [Problem to be solved by the invention]

[0013] As described above, when using carrier particles such as magnetic particles to selectively adhere and separate target cells present in blood, etc., the only option was to use antibodies against membrane antigens of the target cells as a means of selective adhesion. On the other hand, in the method using an antibody against the membrane antigen of the target cell, since an antibody corresponding to the target cell type must be used, there is a problem that the cells that should be captured cannot be captured when the target cell is not necessarily clear or when the target cell is transformed. For example, it has been pointed out that when the antibody clone of the anti-EpCAM antibody used to target CTCs is different, the type of CTC detected will differ. In addition, the above-mentioned EpCAM is not necessarily expressed on all CTCs, and there are problems such as the loss of EpCAM during pretreatment of the separation process, so the results obtained by the method using an antibody against the membrane antigen of the target cell may not necessarily reflect the desired phenomenon. Furthermore, when detaching target cells that have adhered to carrier particles via an antibody, it is necessary to take measures such as replacing the antibody with a specific reagent or detaching only the carrier particles while leaving the antibody on the target cells, which may result in alteration of the target cells and cause problems in subsequent culture and evaluation.

[0014] An object of the present invention is to provide novel particles for cell adhesion that selectively adhere to cells, such as tumor cells and stem cells, present in blood, etc., and enable them to be separated from the blood, etc., without using antibodies, etc., as a means for selectively adhering target cells. Another object of the present invention is to provide a method for selectively adhering and capturing tumor cells, stem cells, etc. present in blood, etc., by using the particles for cell adhesion. [Means for solving the problem]

[0015] In order to solve the above problems, the present invention has the following features. <1> The cell adhesion particles are for adhering highly adhesive cells present in an aqueous solution, and have a hydratable composition on at least a portion of their surface, the intermediate water content of which at saturated water content is 1 to 30 wt%. <2> The particles for cell adhesion have an average particle size of 2 to 500 μm. <3> The highly adhesive cells include tumor cells, stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac myocytes, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, and pancreatic islet cells. <4> The above-mentioned particles for cell adhesion, wherein the above-mentioned hydratable composition is a polymer containing methoxyethyl acrylate. <5> A method for capturing cells, comprising contacting particles having a hydratable composition on at least a portion of their surface, the intermediate water content of which at saturated water content is 1-30 wt %, with a solution containing cells, thereby adhering highly adhesive cells. <6> The method for capturing cells as described above, wherein the average particle size of the cell adhesion particles is 2 to 500 μm. <7> The highly adhesive cells include tumor cells, stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac myocytes, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, and pancreatic islet cells. <8> The method for trapping cells as described above, wherein the hydratable composition is a polymer containing methoxyethyl acrylate. <9> A particle-cell complex comprising a particle having a hydratable composition on at least a portion of its surface, the intermediate water content of which at saturated water content is 1 to 30 wt%, and highly adhesive cells adhered to the surface of the particle. <10> The complex of particles and cells, wherein the particles have an average particle size of 2 to 500 μm. <11> The highly adhesive cells include tumor cells, stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac myocytes, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, and pancreatic islet cells. <12> The particle-cell complex as described above, wherein the hydratable composition is a polymer containing methoxyethyl acrylate. <13> A method for detaching cells from the particle-cell complex, comprising seeding the complex in a cell culture medium. <14> A cell culture method comprising culturing the cells obtained by the above method in a cell culture medium. Effect of the Invention

[0016] By using the particles for cell adhesion according to the present invention, it becomes possible to form a complex by adhering tumor cells, stem cells, etc. as target cells in an aqueous solution such as blood, and it becomes possible to easily separate and recover the cells from the aqueous solution. In particular, by using particles for cell adhesion having a particle diameter of 2 μm or more, the cells will subsequently autonomously detach in the medium, etc., and it becomes possible to separate and recover the desired target cells from blood, etc. while suppressing damage to the cells. [Brief description of the drawings]

[0017] [Figure 1] FIG. 2 is a schematic diagram showing the structure of a water layer formed on the surface of a wettable composition. [Diagram 2] FIG. 2 is a diagram illustrating the characteristics of each layer constituting the water layer formed on the surface of the hydratable composition. [Figure 3A] This is an XPS measurement result of polystyrene particles before PMEA coating. [Figure 3B] 1 shows the XPS measurement results of polystyrene particles after PMEA coating. [Figure 4A] This is an XPS measurement result of magnetic particles before PMEA coating. [Figure 4B] 1 shows the XPS measurement results of the magnetic particles after PMEA coating. [Diagram 5] This shows the change in adhesion rate of HT-1080 cells to cell adhesion particles. [Figure 6A] This is an optical microscope image of HT-1080 cells adhered to cell adhesion particles. [Figure 6B] This is an optical microscope image of HT-1080 cells adhered to cell adhesion particles. [Figure 7] This is the detachment rate of HT-1080 cells from the cell adhesion particles. [Figure 8A] This is an optical microscope image of HT-1080 cells adhered to cell adhesion particles. [Figure 8B] 1 shows optical microscope images of HT-1080 cells detached from cell adhesion particles. [Figure 9A]1 is an SEM image of particles after a platelet adhesion test. [Figure 9B] 1 is an SEM image of particles after a platelet adhesion test. [Figure 9C] 1 is an SEM image of particles after a platelet adhesion test. [Figure 9D] 1 is an SEM image of particles after a platelet adhesion test. [Figure 10] 1 shows optical microscope images of HT-1080 cells detached from cell adhesion particles. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] (1) Intermediate water The present invention is characterized by the use of a hydratable composition that contains water molecules in a state called "intermediate water" when hydrated, as a means for selectively adhering target cells that are mixed with blood cells and the like. Intermediate water is considered to be an aggregate of water molecules contained in the hydratable composition, the degree of freedom of which is restricted by weak interaction with the hydratable composition, etc. It has been confirmed that surfaces on which intermediate water exists exhibit blood compatibility, such as the difficulty of adhesion of blood components such as blood cells. The mechanism by which surfaces on which intermediate water exists exhibit blood compatibility is considered to be as follows. It is believed that the surface of various cells, such as blood cells, contained in blood is stabilized by the formation of a hydration shell, which is believed to suppress unnecessary activation and the like when the cells come into contact with biological tissues, etc. On the other hand, it is believed that the adhesion and activation of the cells to the foreign body surface occurs when the hydration shell is disturbed or destroyed by direct contact with the surface of the foreign body. A typical example of this is the reaction in which platelets, which are stable in blood vessels, become activated when they come into contact with the surface of a foreign body due to bleeding, etc., and cause blood coagulation.

[0019] In contrast, on the surface of a hydratable composition containing intermediate water, the intermediate water forms a kind of hydration shell and acts as a cushioning material that prevents biological materials from directly contacting the surface (Figure 1), so that the degree of disturbance of the hydration shells of cells, proteins, etc. that come into contact with this surface is mild, and as a result, it is thought to result in blood compatibility, such as making it difficult for blood components to adhere. Since it has been confirmed that intermediate water exists within the hydration shells formed by various cell surfaces and proteins, the surface of a hydratable composition containing intermediate water can also be thought to mimic the surface structure of biological tissue.

[0020] The phenomenon in which adhesion of various cells, etc. is suppressed on the surface of a hydratable composition containing intermediate water as described above is particularly notable on the surface of a hydratable composition containing a large amount of intermediate water, and it has been confirmed that it is possible to suppress adhesion of almost all cells, etc. present in blood. It has also been confirmed that BSA, etc., which is listed as a base coating material for preventing non-specific adhesion of biopolymers in the above-mentioned Patent Document 1, contains a high proportion of intermediate water.

[0021] On the other hand, on the surface of a hydratable composition having an intermediate water content of about 1 to 30 wt% when saturated with water, adhesion of blood cells such as platelets is suppressed, while specific cells contained in blood, such as tumor cells, stem cells, and vascular endothelial cells, are observed to adhere. This phenomenon is believed to be the result of the hydration shell of intermediate water being thin on a surface with a low intermediate water content, and therefore only cells having higher adhesive ability than blood cells for some reason exhibit significant adhesion. The threshold value of the intermediate water content that determines whether or not a cell exhibits significant adhesion is determined according to the adhesive ability of the cell, and since normal blood cells have low adhesiveness, it is believed that they have difficulty adhering to the surface of a hydratable composition containing an intermediate water content of about 1 wt% or more. The present inventors have disclosed in Patent Document 3 a technology that utilizes this phenomenon to selectively adhere and separate metastatic cancer cells and other tumor cells, stem cells, vascular endothelial cells, and other cells exhibiting high adhesiveness contained in blood, from blood cells, and other cells.

[0022] In this specification, cells such as tumor cells, stem cells, and vascular endothelial cells that can adhere to the surface of a hydratable composition containing an intermediate water content of about 1 wt% or more may be referred to as "highly adhesive cells." In addition, adhesion of the highly adhesive cells while not substantially adhering blood cells and the like that exist in high density in blood may be simply described as "selective adhesion," etc.

[0023] Furthermore, as disclosed in Patent Document 4, a surface containing intermediate water at a predetermined ratio is also suitable as a substrate for culturing various types of cells. Therefore, compared with the means of adhering specific cells using antibodies as disclosed in Patent Documents 1 and 2, the method disclosed in Patent Document 3 is expected to enable the adhesion and separation of tumor cells and the like while avoiding damage to the cells.

[0024] As described above, by using a hydrated composition having an intermediate water content of about 1 to 30 wt% when saturated with water in the form of a flat membrane, it is possible to selectively adhere highly adhesive cells such as tumor cells, stem cells, and vascular endothelial cells, and separate them from blood cells, etc. Furthermore, by further applying the findings of the flat membrane hydrated composition to adhesion and separation of target cells using carrier particles, it is expected that the increase in specific surface area, etc. will enable efficient adhesion and separation of highly adhesive cells as targets.

[0025] (2) About the particles for cell adhesion according to the present invention However, as discussed in detail in Patent Document 1, for example, when attempting to adhere rare cells present in blood or the like using carrier particles having adhesion means for various cells, a certain amount of stirring or the like is required to ensure the frequency of collision between the carrier particles and the cells, and it is unclear whether various target cells will adhere to the hydratable composition containing intermediate water and whether the adhesion will be maintained in a dynamic environment accompanied by such stirring, etc. In other words, while the adhesion between the hydratable composition and various cells disclosed in Patent Document 3 occurred in a quasi-static environment, it was not necessarily clear whether sufficient adhesion would occur in a dynamic environment.

[0026] In response to this, the present inventors introduced particles containing a predetermined amount of intermediate water on their surface into an aqueous solution containing highly adhesive cells and mixed them, and unexpectedly found that the cells and particles adhered to each other at a sufficient frequency to form a complex, and that the complex could be separated from the aqueous solution by centrifugation, etc. Since platelets did not adhere to the surface of the particles containing intermediate water as in the case of the flat membrane, it was shown that highly adhesive cells present in an aqueous solution such as blood, which are mixed with blood cells, can be selectively adhered and separated by using particles containing a predetermined amount of intermediate water on their surface as in the case of using a flat membrane-shaped hydratable composition, and thus the present invention was arrived at.

[0027] From the above findings, an invention is specified in which particles, at least a part of whose surface is made of a hydratable composition having an intermediate water content of 1-30 wt% at saturated water content, selectively adhere specific cells present in an aqueous solution such as blood to form a complex, which can then be separated from the aqueous solution by means of centrifugation, etc. Also specified is an invention in which particles, at least a part of whose surface is made of a hydratable composition having an intermediate water content of 1-30 wt% at saturated water content, are used for cell adhesion.

[0028] Furthermore, when the complex consisting of the above-mentioned cell adhesion particles and cells was placed in a cell culture medium, it was observed that by setting the particle diameter of the particles in an appropriate range, the cells autonomously detached from the particles and moved onto the medium. In other words, by using cell adhesion particles having a particle diameter of 2 to 3 μm or more, which is equal to or greater than the size of the cells, the cells autonomously detached from the particles at a predetermined rate and moved into the medium by adding the complex of the particles and cells to a cell culture medium and holding it for a predetermined time, it was found that normal cell culture was possible thereafter without performing a treatment that affects the cell surface as described in Patent Document 1. In particular, by setting the particle diameter of the cell adhesion particles to 10 μm or more, it was observed that almost all the cells autonomously detached from the particles within about 2 hours after being placed in the medium, and it became possible to efficiently collect various highly adhesive cells present in blood and the like and use them for biological studies.

[0029] In addition, in the cell adhesion particles according to the present invention, particles having few surface irregularities and relatively nearly spherical shapes are preferably used from the viewpoint of not inhibiting detachment of cells adhered to the particles. The particle size in the present invention is the average particle size measured by DLS (Dynamic Light Scattering) (or SLS (Static Light Scattering)).

[0030] That is, in the cell adhesion particles according to the present invention, it is preferable that the average particle size is 2 to 3 μm or more, since the cells that adhere to and are separated from the particles are then autonomously detached in the cell culture medium. In particular, it is preferable that the average particle size is 5 μm or more, or 10 μm or more, since a high percentage of the cells are autonomously detached from the particles within a short period of time.

[0031] On the other hand, since the cell adhesion particles according to the present invention are used by dispersing (suspending) them in an aqueous solution such as blood, it is preferable to select a particle diameter that is equal to or smaller than the particle diameter that does not cause precipitation in a short time depending on the density of the particles used. For example, when the cell adhesion particles are mainly composed of polymers such as polystyrene, the particle diameter is set to about 500 μm or less, so that the particles can be dispersed in the aqueous solution by gentle stirring. On the other hand, when the central particle of the cell adhesion particles is composed of a high-density substance such as a magnetic particle, the particle diameter is set to about 50 μm or less, so that the particles can be dispersed in the aqueous solution by gentle stirring.

[0032] From the viewpoint of separating the complex obtained by adhering various cells to the cell adhesion particles according to the present invention from the aqueous solution by centrifugation, filtration, etc., it is generally desirable for the particle diameter of the cell adhesion particles to be large within the above range. On the other hand, by forming the central particle of the cell adhesion particles from a high-density substance, separation by centrifugation, etc. is possible even when the particle diameter is fine. In particular, by using a magnetic particle as the central particle, good separation is possible using a magnetic field regardless of the particle diameter.

[0033] It is also preferable that the particle diameter variation of the cell adhesion particles used is small; however, when particles of 2 μm or less are mixed in, the efficiency of the cells adhering to the particles to autonomously detach decreases. Therefore, it is preferable that the particles have an average particle diameter of 2 μm or more, are monodispersible, and have a narrow particle diameter distribution.

[0034] (3) Separation of cells from an aqueous solution using the cell adhesion particles according to the present invention The complex obtained by adhering various cells to the cell adhesion particles according to the present invention in an aqueous solution can be separated from the aqueous solution by various means. For example, the cell adhesion particles containing the complex can be enriched and separated from the aqueous solution by centrifugation. Furthermore, by including magnetic particles in the cell adhesion particles, separation can be achieved using a magnetic field. Furthermore, by using cell adhesion particles having a particular particle size or larger, separation from the aqueous solution can also be achieved by filtration using a filter.

[0035] The cells adhered to the cell adhesion particles separated from the aqueous solution can be used as they are adhered to the cell adhesion particles or detached from the cell adhesion particles depending on the purpose. For example, as described in the above JP 2016-63801 A, a hydratable composition containing intermediate water at a predetermined ratio has excellent properties as a substrate for cell culture, so that cells can be cultured in a medium in a state where they are adhered to the cell adhesion particles according to the present invention. On the other hand, as described above, by using the cell adhesion particles having an average particle size of 2 μm or more among the cell adhesion particles according to the present invention, cells autonomously detach in the medium, so that it is possible to carry out normal cell culture by placing a complex of the cell adhesion particles and the cells in the medium.

[0036] Furthermore, as described in, for example, JP 2016-131561 A, by using a hydratable composition having a lower critical solution temperature (LCST) in a predetermined temperature range as a hydratable composition containing intermediate water, it is possible to separate the target cells from the aqueous solution, and then dissolve the hydratable composition by cooling to a predetermined temperature, thereby detaching the separated target cells from the cell adhesion particles. In addition, cells can be detached from the cell adhesion particles by washing, shaking, treatment with a chelating agent such as EDTA (Ethylenediaminetetraacetic acid) or EGTA (Ethylene glycol tetraacetic acid), ultrasonic treatment, or other means.

[0037] As explained above, by using the particles for cell adhesion according to the present invention, it is possible to form a complex by adhering tumor cells, stem cells, etc., which are present at low density in an aqueous solution such as blood, as target cells, and to easily separate and collect the cells from the aqueous solution. According to the present invention, it is possible to separate and collect target cells without causing any transformation due to the use of antibodies, particularly compared to a method using an anti-EpCAM antibody or the like. In particular, by using particles for cell adhesion having a particle diameter of 2 μm or more, the cells are autonomously detached in the medium or the like thereafter, and it is possible to separate and collect the desired target cells from blood or the like while suppressing further damage to the cells. Each relevant aspect of the present invention will now be described in further detail.

[0038] (4) Method of measuring intermediate water volume The present invention is characterized by using a hydratable composition that contains 1 to 30 wt% intermediate water when it becomes saturated with water upon contact with an aqueous solution such as blood, lymph, or physiological saline. It has been revealed that when a hydratable composition becomes saturated with water, the state of the hydrated water molecules can be broadly classified into three types (Figure 2). The water molecules that are most strongly affected by the hydratable composition are in a state that can be called "crystal water" that is strongly bound by the composition molecules and cannot move freely as water molecules, and since they cannot freeze to form solid water (ice) even when cooled to extremely low temperatures, they are classified as "nonfreezing water." Generally, in the initial stage of water absorption (when the water content is low), all of the absorbed water molecules form nonfreezing water.

[0039] On the other hand, in a hydratable composition saturated with water, there are water molecules that are hardly bound to the composition molecules and behave similarly to water molecules in pure water, and such water molecules are classified as "free water." Free water is characterized by solidifying and dissolving at around 0°C, just like pure water. On the other hand, when hydration compositions such as biological substances such as proteins and certain synthetic polymers are hydrated, it has been shown that water molecules exist that exhibit behavior that cannot be classified as "unfreezable water" or "free water" above, and such water molecules are classified as "intermediate water."

[0040] Intermediate water is typically characterized by a specific release or absorption of latent heat observed during the heating process after supercooling. That is, in a substance containing intermediate water, specific release or absorption of latent heat is observed during the cooling or heating process in the temperature range of -100 to -20°C, such as release of latent heat around -50 to -20°C and absorption of latent heat in the temperature range of -15 to 0°C. Such release or absorption of latent heat can be quantitatively observed by DSC (differential scanning calorimeter) or the like. The release of latent heat in the vicinity of -50 to -20°C corresponds to the latent heat generated when the intermediate water, which solidified in an irregular state during quenching, transforms from irregular to ordered (CC: cold crystallization) during the subsequent gradual heating process. The absorption of latent heat in the temperature range of -15°C to 0°C corresponds to the latent heat generated when the ordered intermediate water undergoes a phase transformation (melting) and the melting of free water.

[0041] The amount of intermediate water contained in the hydratable composition can be calculated from the amount of latent heat transferred (amount of enthalpy change) due to the phase transformation of the intermediate water. Specifically, in the process of observing the amount of latent heat transferred during the process of cooling or heating the water-containing hydratable composition in the temperature range of -100 to -20°C using DSC or the like, the amount of latent heat released (ΔHcc) particularly around -50 to -20°C is measured, and the amount of intermediate water (Wfb) contained in the hydratable composition can be calculated by dividing this amount by the latent heat of fusion of water (Cp: 334 J / g) according to formula (1). Wfb (g) =ΔHcc(J) / Cp (J / g)...Equation (1)

[0042] In addition, when the amount of free water (Wf) contained in the hydratable composition can be calculated, for example, from the amount of latent heat released around 0°C during the cooling process, the amount of absorption expected to be due to free water can be calculated by subtracting the amount of absorption due to melting of regularized intermediate water from the amount of latent heat absorption (ΔHm) in the temperature range of -15°C to 0°C during the heating process, and then dividing this by the latent heat of fusion of water to calculate the amount of intermediate water contained in the hydratable composition. In addition, since the antifreeze water contained in the hydratable composition does not undergo phase transformation within the range of measurement by the above-mentioned DSC, etc., it is difficult to calculate the amount of antifreeze water (Wnf) from the amount of latent heat transferred. Therefore, the amount of antifreeze water contained in the hydratable composition is calculated by subtracting the amount equivalent to intermediate water and free water from the total water content (Wc).

[0043] Since the cell adhesion particles of the present invention are used in contact with aqueous solutions such as blood, the hydration composition on the surface of the cell adhesion particles reaches saturation water content at the time of use, and the intermediate water content at that time is defined as the saturated intermediate water content (SWfb). An example of the results of measurements of the intermediate saturated water content for various hydratable compositions conducted by the present inventors is shown in Table 1. Note that the intermediate saturated water content varies depending on the molecular weight of the polymer used in the measurement and does not correspond to a constant physical property value, so when attempting to produce the particles for cell adhesion according to the present invention, it is desirable to check the intermediate water content for each hydratable composition to be used.

[0044] [Table 1]

[0045] As shown in Table 1, intermediate water is contained in various hydratable compositions, and it is known that the amount of saturated intermediate water varies depending on the molecular structure. It is also known that a large proportion of intermediate water exists in polymers of biological origin, such as BSA. The above PMEA, PMC3A, PHEMA, etc. are all water-insoluble, so by using them on the surface of cell adhesion particles, they can be used to adhere highly adhesive cells. In addition, PMPC contains a high proportion of intermediate water, but it is known that it is water-soluble when used alone. For this reason, it can be made water-insoluble by mixing water-insoluble monomers during synthesis to form a copolymer, and the saturated intermediate water content can be appropriately reduced, making it suitable for use in producing cell adhesion particles by adjusting the intermediate water content.

[0046] (5) Structure of the cell adhesion particles according to the present invention In the particle for cell adhesion according to the present invention, if a hydrating composition having a saturated intermediate water content of 1-30wt% is present on at least a part of the particle surface, it is possible to selectively adhere target cells, and the internal structure is not particularly limited. In other words, the particle for cell adhesion according to the present invention can adopt an appropriate structure, such as a hydrating composition having a saturated intermediate water content of 1-30wt% granulated to a desired particle size by an appropriate means, a hydrating composition having a saturated intermediate water content of 1-30wt% coated on a central particle of an appropriate material, a mixture of a hydrating composition having a saturated intermediate water content of 1-30wt% and fine particles of an appropriate material, etc., granulated to a desired particle size by an appropriate means.

[0047] In particular, by forming a structure in which a hydratable composition having a saturated intermediate water content of 1 to 30 wt% is coated on a central particle of an appropriate material, almost the entire surface of the particle can be made into a cell adhesion particle that is the hydratable composition, while various properties can be added according to the material of the central particle. For example, by using a magnetic particle as the central particle and coating the hydratable composition, it becomes possible to enrich the cell adhesion particles to which the desired target cells are adhered by applying a magnetic field, and to separate them from an aqueous solution, etc. In addition, when separating the cell adhesion particles to which the desired target cells are adhered from an aqueous solution, etc. by centrifugation, it is effective to coat the central particle made of a material having an appropriate unit mass with the hydratable composition.

[0048] Coating of the central particle with the hydratable composition can be performed by any suitable means, and is not particularly limited. For example, a means is used in which the central particle is put into a solution in which the hydratable composition is dissolved in a solvent, and the particles are then separated and dried. In addition, when using a polymer as the hydratable composition, the central particle is put into a solution in which a monomer that produces the polymer by polymerization is dissolved, and polymerization is caused by a polymerization initiator or the like, so that the desired hydratable composition can be coated on the central particle. In addition, it is also desirable to previously treat the surface of the central particle with a treatment or the like to improve the affinity with the hydratable composition.

[0049] In the cell adhesion particles according to the present invention, any hydratable composition having a saturated intermediate water content according to the purpose can be used. For example, organic polymers having a predetermined intermediate water content, inorganic substances such as hydroxyapatite, proteins such as gelatin, collagen, and albumin, polysaccharides such as hyaluronic acid and chondroitin sulfate, etc. can be used. In addition, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polymethylvinyl ether (PMVE), poly(2-methacryloyloxyethyl phosphorylcholine), polytetrahydrofurfuryl acrylate, polyoxazoline, etc., which are known as biocompatible polymers, can be used in a state where their effects on the human body are suppressed. Further, examples of preferred polymers include poly(2-ethoxyethyl acrylate), poly(2-methoxyethyl acrylate), poly[2-(2-methoxyethoxy)ethyl methacrylate], poly[2-(2-ethoxyethoxy)ethyl acrylate], poly[2-(2-methoxyethoxy)ethoxy]ethyl methacrylate], poly[2-(2-(2-methoxyethoxy)ethoxy)ethyl acrylate], poly[2-(2-ethoxyethoxy)ethyl methacrylate], polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polymethylvinyl ether (PMVE), methoxyethyl(meth)acrylamide, methoxyethylvinyl ether, polytetrahydrofurfuryl(meth)acrylate, polyoxazoline, and the like, all of which are represented by the following chemical formula (1).

[0050] [ka] [In the formula, R 1 is a hydrogen atom or a methyl group, R 2 is a methyl or ethyl group, m is 1 to 6, and n is a repeating unit.

[0051] Among these polymers, poly(2-methoxyethyl acrylate (PMEA)) represented by the following chemical formula (2) is particularly preferred because of its excellent biocompatibility.

[0052] [ka]

[0053] Furthermore, the monomers constituting these polymers may be mixed with other monomers to form copolymers, which can be used as materials having a desired intermediate water content.

[0054] Also, for example, poly[2-(2-ethoxyethoxy)ethyl acrylate] (PEEA) has intermediate water and a lower critical solution temperature (LCST) of 14° C., and is characterized by dissolving in an aqueous solution at temperatures below this temperature. In this way, by providing a hydratable composition that contains a predetermined amount of saturated intermediate water and has a lower critical solution temperature (LCST) and changes from hydrophobic to hydrophilic depending on temperature on the surface of cell adhesion particles, it is possible to easily detach the cells by cooling the cell adhesion particles to which the cells have been adhered in an aqueous solution.

[0055] The particles for cell adhesion according to the present invention allow highly adhesive cells present in body fluids such as blood to adhere. Examples of highly adhesive cells include metastatic cancer cells and tumor cells such as leukemia cells contained in blood. The particles can also be used to detect cells such as stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac muscle cells, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, and pancreatic islet cells.

[0056] As described above, whether various cells will adhere to the hydration composition is determined according to the saturated intermediate water content of the hydration composition constituting the particle surface, and by using a hydration composition with a large saturated intermediate water content, adhesion of less adhesive cells is prevented. For this reason, in the particle for cell adhesion according to the present invention, it is desirable to use a hydration composition with a saturated intermediate water content as large as possible within the range in which the target cells of interest can adhere, in terms of improving selectivity. On the other hand, by using a hydration composition with a relatively small saturated intermediate water content of about 3 wt%, adhesion of the majority of cells floating in the blood is suppressed, while rare cells in the blood can be adhered and enriched. For this reason, it is preferable to set the saturated intermediate water content of the surface of the particle for cell adhesion according to the purpose of separating cells using the particle for cell adhesion according to the present invention, or the type of target cells to be separated, and to select and use a hydration composition with the saturated intermediate water content.

[0057] (6) Cell adhesion using the cell adhesion particles according to the present invention The cell adhesion particles according to the present invention are used by adding a predetermined ratio to a body fluid such as blood or lymph, in which the target cells to be separated are expected to be present. For the blood into which the cell adhesion particles are added, appropriate pretreatment such as dilution, enrichment by centrifugation, addition of an anticoagulant, etc. may be performed in advance in order to facilitate the adhesion process between the cell adhesion particles and the target cells. After adding the cell adhesion particles to the sample at a predetermined ratio, it is desirable to carry out stirring under appropriate conditions in order to increase the frequency of collision between the cell adhesion particles and the target cells. The stirring conditions are desirably such that the cell adhesion particles used are dispersed in the sample and do not cause precipitation, and stirring at an excessive speed is undesirable because it increases the relative speed of the cell adhesion particles to the target cells, inhibiting adhesion and causing detachment of the target cells from the cell adhesion particles.

[0058] After stirring in the sample for a predetermined time, the cell adhesion particles to which the target cells are adhered are separated from the sample by an appropriate method. The method for separating the cell adhesion particles can be appropriately determined depending on the size, density, physical properties, etc. of the cell adhesion particles. For example, the cell adhesion particles may be precipitated by centrifugation, or the cell adhesion particles may be separated by filtration using a filter. In addition, by using cell adhesion particles containing a magnetic material, it is also possible to collect the cell adhesion particles by a magnetic field. The collected target cells are preferably protected by subsequently placing the particles for cell adhesion to which they are attached in PBS, etc. In addition, when the particles for cell adhesion according to the present invention, particularly those having a particle diameter of 3 μm or more, are used, the particles to which the target cells are attached can be placed in a cell adhesion medium, whereby the cells autonomously detach, and the target cells can be obtained without being damaged. In addition, the cells can be detached from the particles for cell adhesion by a means used for detaching cells from a substrate, such as treatment with a chelating agent such as EDTA or EGTA, ultrasonic treatment, shaking, washing, etc., and subjected to various evaluations.

[0059] Since the cells detached from the cell adhesion particles include multiple types of cells present in blood, etc., it is preferable to select and separate the target cells under a microscope for use. Among the separated cells, particularly tumor cells, the counting results can be used as an indicator for knowing the extent and characteristics of tumor progression and the possibility of metastasis. In addition, by culturing and growing the tumor cells detached from the cell adhesion particles, they can be used to identify the primary tumor site and to screen candidate substances for anticancer drugs that are expected to have medicinal effects. In addition, stem cells, etc. can be used in regenerative medicine by culturing them under a specified environment.

[0060] The cell adhesion particles according to the present invention can be packed into a column and used to separate target cells. Specifically, for example, the target cells can be separated from a sample such as a body fluid through a process of adsorbing the target cells to the cell adhesion particles in the column and a process of eluting the target cells from the cell adhesion particles in the column. The size of the column, the conditions for adsorbing the target cells to the cell adhesion particles in the column, the conditions for eluting the target cells from the cell adhesion particles in the column, etc. can be appropriately set. In the step of adsorbing the target cells to the cell adhesion particles in the column, as described above, for example, a body fluid or the like containing the target cells may be brought into contact with the cell adhesion particles packed in the column. The body fluid or the like may be previously subjected to dilution, centrifugation, appropriate pretreatment, or the like. In the step of eluting the target cells from the cell adhesion particles in the column, as described above, for example, the culture medium may be used as the eluent, or an eluent containing a chelating agent may be used, or any other appropriate means may be adopted. EXAMPLES

[0061] The present invention will be specifically described below with reference to examples, but the present invention is not limited to the following examples.

[0062] 1. Synthesis of hydratable composition and measurement of intermediate water content Poly(2-methoxyethyl acrylate) (PMEA) material, which is known to contain intermediate water when hydrated, was synthesized by the following procedure. 15g of 2-methoxyethyl acrylate was polymerized in 60g of 1,4-dioxane with azobisisobutyronitrile (0.1% by weight) as an initiator at 75°C for 10 hours while bubbling with nitrogen. After the polymerization reaction was completed, the product was isolated by dropping it into n-hexane to precipitate it. The product was dissolved in tetrahydrofuran and purified twice using n-hexane. The purified product was dried under reduced pressure for a day and night. A colorless, transparent, starch syrup-like polymer was obtained. The yield was 12.3g (82%). The structure of the obtained polymer was confirmed by 1H-NMR. The molecular weight analysis by GPC showed that the number average molecular weight (Mn) was 26,000 and the molecular weight distribution (Mw / Mn) was 3.27. PMEA is soluble in methanol and insoluble in water.

[0063] The synthesized PMEA was immersed in water for a maximum of 7 days to sufficiently hydrate it, and the saturated intermediate water content in PMEA was measured by the following method. The measurement was performed by taking a predetermined amount of the hydrated hydratable composition sample, spreading it thinly on the bottom of an aluminum oxide pan whose weight had been measured in advance, and measuring the amount of heat absorbed and generated by the hydratable composition sample in the process of changing the temperature in a differential scanning calorimeter (DSC). The measurement in the differential scanning calorimeter was performed by first cooling from room temperature to -100°C at a cooling rate of 5°C / min and holding for 10 minutes, and then heating from -100°C to 50°C at a heating rate of 5°C / min, and measuring the amount of heat absorbed and generated as a function of temperature. The total amount (g) of intermediate water contained in the hydratable composition sample was calculated from the amount of latent heat released (ΔHcc) at around -50 to -20°C according to the above formula (1).

[0064] Next, the water weight (Wl:g) of the hydratable composition sample was measured after the DSC measurement, and then the dry weight (Wo:g) after thoroughly drying in a vacuum through a pinhole in an aluminum oxide pan was measured, and the weight loss was taken as the water content (Wc:g) of the hydratable composition sample.Then, the total amount (g) of the intermediate water was divided by the dry weight (Wo:g) of the hydratable composition sample to calculate the intermediate water content (wt%) contained in the hydratable composition sample. In order to avoid various measurement errors, the above measurements were performed multiple times, and the maximum value of the intermediate water content obtained was taken as the saturated intermediate water content (SWfb) of PMEA. The saturated intermediate water content of PMEA used in the following evaluation was 4.0 wt%.

[0065] 2. Manufacturing of particles for cell adhesion Using magnetic particles having various particle sizes and polystyrene particles as the central particles, the surface of the central particles was coated with the polymer (PMEA) synthesized above by the following procedure to produce particles for cell adhesion. Note that particles manufactured by Thermo Fisher Scientific (product numbers: DB6550, DB14203, DB14011) were used as the magnetic particles (particle size: 1.0, 2.8, 4.5 μm). Also, particles manufactured by Poly sciences (product numbers: 18329-5, 07315-5, 19825-1) were used as the polystyrene particles (particle size: 20, 90, 200-300 μm). Also, it was confirmed in advance that the polystyrene particles and magnetic particles used did not contain intermediate water.

[0066] For each particle dispersed in the aqueous solution, the washing procedure of removing the supernatant by centrifugation and adding methanol was repeated three times to replace the dispersion medium with methanol. Then, each particle from which the supernatant was removed by centrifugation was placed in a PMEA methanol solution (PMEA concentration: 0.2 wt%), attached to a rotator and gently stirred for one day. Then, the procedure of removing the supernatant by centrifugation and adding distilled water was repeated three times to replace the dispersion medium with distilled water. Furthermore, the procedure of removing the supernatant by centrifugation and adding phosphate buffered saline (PBS) was repeated three times to replace the dispersion medium with PBS, and then stored at 4°C. In the obtained dispersion, each particle was dispersed as a monodisperse.

[0067] Figures 3 and 4 show the results of XPS (X-ray Photoelectron Spectroscopy) measurements of polystyrene particles (20 μm) and magnetic particles (4.5 μm) before and after the PMEA coating, respectively. XPS measurements were performed using samples prepared by dispersing the PMEA-coated particles in PBS, coating them on glass plates, and drying them in a thermostatic chamber (37°C) for about 10 hours, using AlKα radiation (1486.7 eV) as the X-ray source. For comparison, the particles as received, without PMEA coating, were redispersed in PBS, and similar XPS measurements were performed using these particles, which were then coated and dried on glass plates.

[0068] As shown in Figures 3 and 4, there was a clear change in the XPS measurement results before and after PMEA coating for both polystyrene particles and magnetic particles, and approximately the same measurement results were obtained for polystyrene particles and magnetic particles that had been coated with PMEA. In addition, the peak around 535 eV that was prominently observed in the polystyrene particles and magnetic particles after PMEA coating was identified as being derived from oxygen atoms (O1s), and the peak around 287 eV was identified as being derived from carbon atoms (C1s), so it was inferred that the surfaces of both particles were coated with PMEA by the PMEA coating process.

[0069] 3. Evaluation of adhesion of cancer cells to various particles and the effects of adhesion on cells In order to evaluate the possibility of adhering and isolating CTCs present in blood, human fibrosarcoma cells (HT-1080) present in PBS were used to evaluate the cell adhesiveness of the cell adhesion particles according to the present invention and the state of cells that adhered to the particles and were separated. The human fibrosarcoma cells used for the evaluation were seeded in a medium containing 10% fetal bovine serum (FBS) and cultured in an incubator at 37°C and in a 5% carbon dioxide atmosphere, and were subcultured by detaching the cells with 0.25% EDTA / Trypsin every 3 days and reseeding them at 1 / 8, until they reached about 80% confluence.

[0070] (1) Cell adhesion test using various particles The medium was removed from the HT-1080 cells cultured as described above, and the medium was washed with an appropriate amount of PBS. An appropriate amount of 0.25% EDTA / Trypsin was then added and the cells were allowed to stand at 37°C in a 5% carbon dioxide atmosphere for 1 to 2 minutes. An appropriate amount of 10% FBS-containing medium was then added to suspend the cells, and the cells were collected in a centrifuge tube and centrifuged at room temperature at 1000 rpm for 3 minutes to remove the supernatant, and PBS was added to resuspend the cells. The cells were centrifuged again to remove the supernatant, and then washed by adding PBS to prepare a PBS suspension of HT-1080 cells (cell concentration in the suspension: 2 × 10 6The cell concentration was measured using a TC20 fully automated cell counter (BIORAD, 1450101J1).

[0071] The PBS suspension of the above-mentioned HT-1080 cells was mixed with the PBS suspension of the various PMEA-coated particles prepared above, and the mixture was placed on a rotator and stirred to allow adhesion of the various particles to the HT-1080 cells. In the above cell adhesion test, 5 × 10 5 A dispersion liquid in which various particles in the number shown in Table 2 were dispersed was mixed with HT-1080 cells (0.25 ml of suspension), placed in a tube, and fixed to a rotator and rotated at 3 rpm at room temperature for a specified time to allow the HT-1080 cells to adhere to the various particles. The number of each particle was adjusted so that the total area was approximately the same. After the specified time had elapsed, the cell adhesion particles were precipitated and separated by centrifugation, and the number (concentration) of cancer cells contained in the supernatant was measured, and the adhesion rate of cancer cells to each type of particle was calculated by comparing it with the number of cancer cells added.

[0072] [Table 2]

[0073] Figure 5 shows the change in adhesion rate of HT-1080 cells to various particles when the mixing time of various particles and cancer cells is changed. Table 3 shows the adhesion rate of HT-1080 cells when the mixing time of various particles and cancer cells is 15 minutes and 120 minutes.

[0074] [Table 3]

[0075] As shown in Figure 5 and Table 3, it was shown that by mixing for 30 minutes or more, a high proportion of HT-1080 cells were attached to the particles and could be separated from the solution, regardless of particle size. In particular, it was shown that by using particles with a particle size of about 10 μm or more, a sufficient proportion of HT-1080 cells could be attached even with short mixing times of about 15 minutes.

[0076] (2) Evaluation of cell adhesion morphology The particles with HT-1080 cells attached by the above procedure were separated by centrifugation and precipitated, washed with PBS, and then seeded in medium without fetal bovine serum (FBS). The morphology of the HT-1080 cells attached to the particles was observed using an optical microscope. Figure 6 shows optical microscope images of HT-1080 cells adhering to particles with diameters of 4.5 μm and 20 μm. For 4.5 μm particles, adhesion between the cells and particles was observed in the form of multiple particles adhering to the periphery of each cell. On the other hand, for particles with diameters of 20 μm or more, each particle maintained a monodispersed state even after mixing with the cells, and HT-1080 cells were observed adhering to each monodispersed particle. In addition, HT-1080 cells that were not adhering to particles were also observed in the medium, suggesting the possibility that HT-1080 cells autonomously detach from the particles after the particles are separated by centrifugation.

[0077] (3) Evaluation of autonomous cell detachment from adhesive particles From the above observations, it was found that the adhesion form of HT-1080 cells changes depending on the particle size of the cell adhesion particles used, and that when the particle size is particularly large, HT-1080 cells autonomously detach from the particles in the medium. Therefore, as described below, we evaluated the phenomenon of HT-1080 cells being separated from PBS by adhering to particles and then detaching from the particles. The various particles coated with PMEA were mixed in PBS suspension with HT-1080 cells in the same manner as above so that the number of particles was as shown in Table 4, and the mixture was placed on a rotator and stirred for 120 minutes to allow HT-1080 cells to adhere to each particle. After that, the particles were precipitated and separated by centrifugation or a magnetic field to prevent non-adhered cells from being mixed with the particles, washed with PBS, and then seeded in a medium not containing fetal bovine serum (FBS) and cultured in an incubator at 37°C under a 5% carbon dioxide atmosphere for 2 hours, after which the proportion of HT-1080 cells detached from the particles was counted using an optical microscope. The counting was performed by visually counting the number of cells that remained attached to the particles and the number of cancer cells that had detached from the particles and migrated into the medium within the range observed in the field of view of an optical microscope (10x).

[0078] [Table 4]

[0079] Figure 7 shows the detachment rate of HT-1080 cells for each particle size. Figure 8 shows optical microscope photographs of the particles and cells observed above. As shown in Figure 7, the ratio of cells that adhere to the particles and autonomously detach from them changes depending on the particle size used. When 1.0 μm particles were used, the particles aggregated while remaining attached to the cells, and almost no HT-1080 cells existed alone in the medium (Figure 8A). On the other hand, when 4.5 μm particles were used, approximately 70% of the HT-1080 cells were observed to autonomously move into the medium, and when 20 μm particles were used, it was observed that almost all of the cells autonomously detached from the particles by holding them in the medium (Figure 8B).

[0080] 4. Adhesion test of human platelets to various particles To evaluate the possibility of isolating CTCs and other particles present in blood from aqueous solutions by separating them from blood cells such as platelets and selectively adhering to them, the degree of platelet adhesion to various particles was confirmed. The human platelets used for the evaluation were prepared as follows. Human whole blood was centrifuged (1500 rpm, 5 min) and the supernatant was collected to obtain platelet-rich plasma (PRP), a plasma component containing a large amount of platelets. Separate human whole blood was centrifuged (4000 rpm, 10 min) and the supernatant was similarly collected to obtain platelet-poor plasma (PPP), a plasma component containing few platelets. PRP was diluted with PPP, and a human platelet solution (platelet density: 1.0 × 10 8 A concentration of 100 μg / ml was prepared. 0.5 ml of the above human platelet solution (platelet count: 0.5 × 10 8 For each sample (100 pieces), magnetic particles (DN) and polystyrene particles (PS) with or without PMEA coating in the numbers shown in Table 5 were mixed in a tube, fixed to a rotator and rotated at 3 rpm at room temperature for 60 minutes, after which the concentration of human platelets in the supernatant was measured and converted into the adhesion rate of human platelets to each type of particle.

[0081] [Table 5]

[0082] Table 5 shows the adhesion rate of human platelets to the various particles evaluated above. As shown in Table 5, by mixing particles without PMEA coating for 60 minutes, it was observed that 50% or more of the platelets adhered to the particles, regardless of the particle size, etc. On the other hand, with the particles coated with PMEA, substantially no reduction in the number of platelets in the human platelet solution after mixing was observed, indicating that the frequency of platelet adhesion to the particles was low.

[0083] In order to confirm the adhesion of platelets to the particle surface, the various particles after the platelet adhesion experiment were washed with phosphate buffer, then 1% glutaraldehyde solution was added and suspended, and the particles were fixed to a rotator and rotated at 3 rpm at room temperature for 60 minutes to fix the platelets that had adhered to the particle surface to the particles. The particles were then washed with phosphate buffer, pure water, and ethanol, placed on a PET substrate, and air-dried. The PET substrate was fixed to a sample stage dedicated to SEM (Scanning Electron Microscope) using conductive tape, and platinum-palladium was vacuum-deposited on the sample surface using an ion coater to prepare a sample for SEM observation, which was observed with an SEM (KEYENCE, VE-7800).

[0084] The results of SEM observation of the particles after the above-mentioned platelet adhesion test are shown in Figure 9. As shown in Figure 9, the presence of significant adhesion was observed on the particle surface without PMEA coating compared to the particles coated with PMEA, which indicates that the PMEA coating inhibits platelet adhesion to the particle surface regardless of the particle material or particle size. The above results suggest that when magnetic particles or polystyrene particles without a PMEA coating are mixed into blood, platelets and other cells present in high density in the blood will preferentially adhere to the particle surface, making it effectively difficult for rare cells such as cancer cells and stem cells to adhere.

[0085] In contrast, in the case of particles having PMEA on the surface, which contains a predetermined amount of intermediate water when hydrated, substantially no platelet adhesion was observed, whereas tumor cells and the like frequently adhered, indicating that selective cell adhesion occurs. This result is similar to the evaluation result of a flat membrane sample reported by the present inventors in Patent Document 3, and suggests that the presence of intermediate water on the particle surface causes a predetermined cell to selectively adhere depending on the amount of intermediate water. It is also suggested that the use of particles that contain an amount of intermediate water on the surface according to the adhesion target when hydrated makes it possible to selectively adhere cancer cells, stem cells, and the like in blood, where blood cells exist at a high density.

[0086] 5. Cancer cell adhesion test in simulated blood As described above, by using particles having a hydratable composition on their surface that contains a predetermined amount of intermediate water upon hydration, it is possible to selectively adhere tumor cells, etc., and it has been suggested that by making the particle diameter approximately 3 μm or more, the adhered cells will autonomously detach and migrate to the surface of a culture dish, etc., allowing subsequent cultivation to be carried out successfully. For this reason, in the following, we mixed the cell adhesion particles of the present invention into an environment where tumor cells and platelets were mixed, and actually attempted to distinguish the tumor cells from the platelets, selectively adhere to them, and separate them, and then recover them in the culture medium.

[0087] The PBS suspension of the above HT-1088 cells (cell concentration in the suspension: 2.0 × 10 6 The dispersion medium of HT-1080 cells (cell concentration: 2.0 × 10 cells / ml) was replaced with the above-mentioned plasma component PPP, and then the platelet-rich plasma component PRP was mixed. 6 cells / ml) and human platelets (platelet concentration: 1.0 × 10 8 A suspension containing 2.3 × 10 β-lactams / ml was prepared. 5 9.0×10 polystyrene particles (particle size: 20 μm) 5 The cells were mixed in a tube as a PBS suspension at a concentration of 1000 cells / ml and rotated at 3 rpm for 60 minutes at room temperature in a rotator. The concentrations of HT-1080 cells and human platelets in the supernatant were then measured and converted into adhesion rates to each particle.

[0088] Furthermore, in order to confirm the state of the HT-1080 cells that had adhered and been separated by the cell adhesion particles, the same mixture as above was rotated for 120 minutes, and then the cell adhesion particles were precipitated and separated by centrifugation, the supernatant was discarded, and the cells were washed with PBS. After that, the cells were seeded in a medium that did not contain fetal bovine serum (FBS) and cultured in an incubator at 37°C in a 5% carbon dioxide atmosphere for 24 hours, and the state of the cells was observed under an optical microscope. Table 6 shows the adhesion rates of HT-1080 cells and human platelets measured above. Also, Fig. 10 shows optical microscope photographs of HT-1080 cells observed above. As shown in Table 6, PMEA-coated particles with a particle diameter of 20 µm caused a high rate of adhesion of HT-1080 cells while suppressing platelet adhesion, demonstrating that the selective adhesion of tumor cells is possible with the cell adhesion particles according to the present invention.

[0089] [Table 6]

[0090] Furthermore, as shown in Figure 10, when the separated particles were seeded in a medium and cultured, the HT-1080 cells adhered to the particles were observed to autonomously detach from the particles, adhere to the cultured blood, and spread out. Therefore, it is possible to use the cells captured by the cell adhesive particles of the present invention for various evaluations by culturing them.

Claims

1. A particle for cell adhesion for adhering cells present in an aqueous solution, comprising: A hydratable composition having an intermediate water content of 1 to 30 wt % when saturated with water is provided on at least a portion of the surface, The average particle size of the particles for cell adhesion is 4.5 to 500 μm.

2. The cell adhesion particle according to claim 1, wherein the cells include tumor cells, stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac myocytes, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, and pancreatic islet cells.

3. 3. The cell adhesion particles according to claim 1, wherein the hydratable composition is a polymer containing methoxyethyl acrylate.

4. The method comprises the steps of contacting a particle having a hydratable composition having an intermediate water content of 1 to 30 wt % at a saturated water content on at least a part of the surface with a solution containing cells to adhere the cells to the particle, A method for capturing cells, wherein the particles have an average particle size of 4.5 to 500 μm.

5. The method for capturing cells according to claim 4, wherein the cells include tumor cells, stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac myocytes, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, or pancreatic islet cells.

6. The method for capturing cells according to claim 4 or 5, wherein the hydratable composition is a polymer containing methoxyethyl acrylate.

7. The present invention comprises a particle having a hydratable composition having an intermediate water content of 1 to 30 wt % at the time of saturated water content on at least a part of the surface thereof, and a cell attached to the surface of the particle, A particle-cell complex, wherein the particles have an average particle size of 4.5 to 500 μm.

8. The particle-cell complex of claim 7, wherein the cells include tumor cells, stem cells, vascular endothelial cells, nerve cells, macrophages, dendritic cells, monocytes, neutrophils, smooth muscle cells, fibroblasts, cardiac myocytes, skeletal muscle cells, hepatic parenchymal cells, hepatic non-parenchymal cells, and pancreatic islet cells.

9. The particle-cell complex according to claim 7 or 8, wherein the hydratable composition is a polymer containing methoxyethyl acrylate.

10. A method for detaching cells from a complex of a particle and a cell according to any one of claims 7 to 9, comprising seeding the complex in a medium for cell culture.

11. A method for culturing cells, comprising obtaining cells by the method according to claim 10 and culturing the cells in a medium for cell culture.

Citation Information

Patent Citations

  • Methods and Reagents for Rapid and Efficient Isolation of Circulating Cancer Cells

    JP2002503814A

  • Bead for culturing animal cell

    JP2003189848A

  • Microparticles carrying cells and agents

    JP2005525407A

  • Method for selecting undifferentiated cell

    JP2010104350A

  • Method for separating cell, for separating cell from solution, and hydratable composition for cell sorting

    JP2012105579A

Cited By

  • Polymer compound and use thereof

    JP2026052039A